{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:07:41Z","timestamp":1779084461364,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vedolizumab (VDZ), a gut-selective anti-integrin therapy, has demonstrated efficacy in ulcerative colitis (UC) clinical trials, but real-world long-term data from Asia, particularly from Chinese populations, remain limited. Therefore, this study aimed to evaluate the long-term effectiveness and safety of vedolizumab in Chinese patients with UC in a real-world setting over a 2-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study conducted at a tertiary hospital in China, patients aged \u226518\u202fyears old who received VDZ for UC between December 2020 and August 2023 were enrolled. Information on the clinical characteristics, prior\/concomitant treatment, and safety during the observation period was collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The data obtained from 112 patients (males,\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f62) were analyzed. The median age at VDZ induction was 40.37\u202fyears old. VDZ was indicated as the first biologic in 85.71% of patients. Clinical remission rates at weeks 14, 54, and 104 were 61.61, 66.96, and 58.93%, respectively. VDZ persistence was 78.57% at 1\u202fyear and 61.61% at 2\u202fyears. Concomitant use of 5-ASA or steroids was associated with poorer drug persistence (HR\u202f=\u202f3.13 and 5.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01). Clinical response at week 14 predicted sustained remission (OR\u202f=\u202f6.07,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Nine adverse drug reactions (ADRs) were noted, none severe.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This real-world study confirms vedolizumab\u2019s sustained effectiveness in UC, with durable remission and excellent safety over 2\u202fyears. The findings support its position in treatment algorithms and highlight the value of early response assessment in guiding therapeutic decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1795200","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:41:56Z","timestamp":1779082916000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term effectiveness and safety of vedolizumab in ulcerative colitis: a real-world retrospective cohort study over 2\u202fyears"],"prefix":"10.3389","volume":"13","author":[{"given":"Peipei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengfu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1053\/j.gastro.2018.12.008","article-title":"AGA technical review on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Singh","year":"2019","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/ecco-jcc\/jjz042","article-title":"Real-world effectiveness and safety of Vedolizumab for the treatment of inflammatory bowel disease: the Scottish Vedolizumab cohort","volume":"13","author":"Plevris","year":"2019","journal-title":"J Crohns Colitis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/ecco-jcc\/jjw177","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"749.1","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1007\/s10620-017-4549-3","article-title":"Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab","volume":"62","author":"Allegretti","year":"2017","journal-title":"Dig Dis Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2014a nationwide consecutive German cohort study","volume":"43","author":"Baumgart","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"17562848241258372","DOI":"10.1177\/17562848241258372","article-title":"Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis","volume":"17","author":"Gros","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nrgastro.2016.128","article-title":"Current best practice for disease activity assessment in IBD","volume":"13","author":"Walsh","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000549358","article-title":"Long-term outcomes and prognostic factors for vedolizumab-treated Japanese patients with ulcerative colitis","volume":"11","author":"Fukushima","year":"2025","journal-title":"Inflamm Intest Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/apt.14930","article-title":"Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry","volume":"48","author":"Chaparro","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"17562848251356063","DOI":"10.1177\/17562848251356063","article-title":"A systematic review of vedolizumab in treating pediatric ulcerative colitis: efficacy and safety insights","volume":"18","author":"Abu Hammour","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.3390\/biomedicines10102526","article-title":"Early clinical remission is a predictor of Long-term remission with the use of vedolizumab for ulcerative colitis","volume":"10","author":"Haga","year":"2022","journal-title":"Biomedicine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12876-025-03913-z","article-title":"Vedolizumab-steroid combination therapy improves long-term prognosis in patients with ulcerative colitis","volume":"25","author":"Yamada","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1093\/ibd\/izaf088","article-title":"Lack of efficacy of concomitant 5-Aminosalicylic acid with Vedolizumab in inflammatory bowel disease: a large-scale administrative database analysis","volume":"31","author":"Nishida","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1136\/gutjnl-2022-327002","article-title":"Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease","volume":"71","author":"Kirchgesner","year":"2022","journal-title":"Gut"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.cgh.2024.04.019","article-title":"Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial","volume":"22","author":"Pudipeddi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cgh.2021.08.047","article-title":"Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults","volume":"20","author":"Kochar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12876-024-03378-6","article-title":"Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY","volume":"24","author":"Krugliak","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1795200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:41:59Z","timestamp":1779082919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1795200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1795200"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1795200","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"1795200"}}